低剂量连续性肾脏替代治疗与危重急性肾损伤患者死亡率:回顾性队列研究
该单中心回顾性队列纳入2012–2021年日本某三级大学医院494例接受CKRT的危重AKI患者,中位年龄72岁,急性肾小管损伤占81.8%,中位实际CKRT剂量13.2mL/kg/h,92.3%低于20mL/kg/h;多因素Cox回归显示低于中位剂量组90天死亡率更高(HR 1.73,95%CI 1.19–2.51,P=0.004)。
要点
- 本队列中位实际CKRT剂量仅13.2mL/kg/h,92.3%患者低于KDIGO推荐的20–25mL/kg/h。
- 低于中位剂量组90天死亡风险显著升高(HR 1.73,95%CI 1.19–2.51)。
- 以连续变量分析,CKRT剂量与90天死亡率呈显著非线性负相关。
核心结论
- 在多数实际剂量低于KDIGO推荐的危重AKI患者中,较低的实际CKRT剂量与更高的90天死亡率独立相关。
研究设计与样本
- 单中心回顾性队列研究,纳入2012年1月1日至2021年12月31日日本某三级大学医院ICU接受CKRT的危重AKI患者494例。
- 暴露为实际CKRT剂量低于或高于中位数,结局为CKRT启动后90天死亡率,分析采用多因素Cox回归和Kaplan-Meier分析。
主要发现
- 研究人群494例,中位年龄72岁,男性309例(62.6%),急性肾小管损伤占81.8%,中位实际CKRT剂量13.2mL/kg/h。
- 456例(92.3%)实际CKRT剂量低于20mL/kg/h,204例(41.3%)在CKRT启动后90天内死亡。
- 多因素Cox回归显示低于中位剂量组死亡率升高(HR 1.73,95%CI 1.19–2.51,P=0.004)。
- 将实际CKRT剂量作为连续变量时,观察到其与90天死亡率呈显著非线性负相关。
关键数值与推荐
- KDIGO指南推荐实际CKRT剂量为20–25mL/kg/h。
- 本研究队列中位实际CKRT剂量为13.2mL/kg/h,92.3%患者低于20mL/kg/h。
- 低于中位剂量与90天死亡率升高相关:HR 1.73(95%CI 1.19–2.51),P=0.004。
临床怎么用
- 在危重AKI患者行CKRT时,应关注实际交付剂量而非仅处方剂量,避免实际剂量过低。
- 对实际CKRT剂量明显低于KDIGO推荐范围的患者,需评估剂量不足与死亡风险的关联并优化治疗。
局限性
- 单中心、回顾性、观察性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Continuous kidney replacement therapy (CKRT) is preferred when available for hemodynamically unstable acute kidney injury (AKI) patients in the intensive care unit (ICU). The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend a delivered CKRT dose of 20-25mL/kg/h; however, in Japan the doses are typically below this recommendation due to government health insurance system restrictions. This study investigated the association between mortality and dose of CKRT. STUDY DESIGN: Single-center retrospective cohort study. SETTING & PARTICIPANTS: Critically ill patients with AKI treated with CKRT at a tertiary Japanese university hospital between January 1, 2012, and December 31, 2021. EXPOSURE: Delivered CKRT doses below or above the median. OUTCOME: 90-day mortality after CKRT initiation. ANALYTICAL APPROACH: Multivariable Cox regression analysis and Kaplan-Meier analysis. RESULTS: The study population consisted of 494 patients. The median age was 72 years, and 309 patients (62.6%) were men. Acute tubular injury was the leading cause of AKI, accounting for 81.8%. The median delivered CKRT dose was 13.2mL/kg/h. Among the study participants, 456 (92.3%) received delivered CKRT doses below 20mL/kg/h, and 204 (41.3%) died within 90 days after CKRT initiation. Multivariable Cox regression analysis revealed increased mortality in the below-median group (HR, 1.73 [95% CI, 1.19-2.51], P=0.004). Additionally, a significant, inverse, nonlinear association between 90-day mortality and delivered CKRT dose was observed using delivered CKRT dose as a continuous variable. LIMITATIONS: Single-center, retrospective, observational study. CONCLUSIONS: A lower delivered CKRT dose was independently associated with higher 90-day mortality among critically ill patients who mostly received dosing below the current KDIGO recommendations. PLAIN-LANGUAGE SUMMARY: The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend delivering a continuous kidney replacement therapy (CKRT) dose of 20-25mL/kg/h. However, it is not clear if it is safe to use delivered CKRT doses below this recommendation. In this study, over 90% of the patients received CKRT with a delivered dose below the KDIGO recommendation. We divided these patients into 2 groups based on the median delivered CKRT dose. Our findings show that a delivered CKRT dose below the median was associated with increased risk of death within 90 days. These findings show that a lower delivered CKRT dose was independently associated with higher 90-day mortality among critically ill patients who mostly received dosing below current KDIGO recommendations.
引用
- Okamoto K, Fukushima H, Kawaguchi M, et al. Low-Dose Continuous Kidney Replacement Therapy and Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Cohort Study. Am J Kidney Dis. 2024. PMID: 38490319. doi:10.1053/j.ajkd.2024.01.526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。